Reportlinker Adds Drug Delivery Technologies: Commercial Prospects 2010-2025
NEW YORK, Dec. 1, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Drug Delivery Technologies: Commercial Prospects 2010-2025
http://www.reportlinker.com/p0335692/Drug-Delivery-Technologies-Commercial-Prospects-2010-2025.html
How will the drug delivery sector develop from 2010, and where will you find the greatest opportunities? How will technology suppliers and drug companies benefit? We show you opportunities for revenue growth for suppliers and users of drug delivery technologies. You can have our report today, staying ahead.
Our new report shows you trends to watch. Novel and generic drug producers can benefit from emerging and established drug delivery technologies. Developments will occur for biotech drugs and small-molecule agents. We analyse commercial trends for:
• Oral drug delivery systems
• Inhalation-based systems
• Transdermal systems
• Injectable systems
• Implanted systems
• Ocular and nasal systems.
The market for drug delivery technologies has been growing rapidly, but which segments will grow fastest? What are the commercial trends to watch? How will the worldwide industry and market perform from 2010 to 2025? Our report answers those and other questions about this important pharma and biotech sector.
We show how you can benefit from the sector. There remain unmet therapeutic needs. Drugs with improved delivery can gain significant market shares from 2010 onwards, increasing competitiveness and extending product lifecycles.
The drug delivery industry and market can expand from 2010 onwards. Our report shows how you could benefit, saving your time and aiding your work. We show you opportunities by therapeutic area.
You can find out how the drug delivery technology market will grow and study trends that are driving this sector. Our study will show you its technological and commercial potential from 2010 onwards.
Industry and market analysis to save you time and aid your decisions
Our new report examines the drug delivery sector critically. We harness primary and secondary research to meet your needs. We provide revenue forecasts, market share analyses, pipeline developments and other data. You can discover strengths, weaknesses, opportunities and threats in the sector. We include 90 tables and figures and two expert interviews - shown in the contents lists with this message.
How you can benefit from Drug Delivery Technologies: Commercial Prospects 2010-2025
Our report gives you the following benefits in particular:
• You will receive hard data for the drug delivery sector, including our revenue predictions for 2010 to 2025
• You will discover revenue analyses for the overall market and its main components from 2009 to 2025, helping you to stay ahead
• You will discover revenue trends for leading national markets from 2009 to 2025 (US, Japan, UK, Germany, France, Spain, Italy, China and India)
• You will find out how the sector will change and adapt from 2010 to 2025
• You will assess leading organisations in drug delivery, discovering their activities and prospects
• You will investigate the drivers, restraints, competition and opportunities influencing drug delivery technologies from 2010 onwards
• You will analyse opportunities for established companies and new market entrants
• You will receive expert views from our survey, including interview transcripts
• You will find out where drug delivery is heading - technologically and commercially - from 2010 onwards.
Our study gives you answers and trends - we aim to save you time and aid your decisions.
You can have this report today
Our new report can benefit everybody interested in drug delivery and related technologies. We forecast commercial potential, discovering trends. Do you want to harness those opportunities? You can stay ahead by ordering our report now. Please let us know how we can help.
Table of Contents
1. Executive Summary
1.1 Drug Delivery Technology Market Review
1.2 Aims, Scope and Format of the Report
1.3 Research & Analysis Methods
2. Introduction
2.1 Introduction to Drug Delivery Technologies (DDT)
2.2 Types of Technologies for Drug Delivery
2.2.1 Sustained/Controlled Release Systems
2.2.2 Injection
2.2.3 Needle-Free Injection
2.2.4 Pulmonary, Buccal and Nasal Delivery
2.2.5 Pills and Capsules
2.3 The World Biotech Market
2.3.1 Summary of the World Biotech Market
2.3.2 The Biotech Industry is Strong
2.4 Biotech Drugs with Associated Drug Delivery Technologies
2.4.1 Pegylated Interferons
2.4.2 A Crowded Insulin Market Has Forced Investment in DDT
2.5 Exubera - A Case Study for Alternative Biological Delivery Methods
2.5.1 Exubera, the First Inhaled Insulin
2.5.2 Description and Development History
2.5.3 Generex and MannKind Developing Next-Generation Oral Insulins
2.5.4 Cost, Caution and Complicated Dosing Could Restrict Afrezza and Oral-lyn
2.6 The Main Challenges for Biological Drug Delivery
3. Leading Markets for Drug Delivery Technology
3.1 The World Drug Delivery Technology Market in 2010
3.2 Growing Market for Drug Delivery Technology and Services
3.2.1 Revenue Forecast for Overall Drug Delivery Technology Market, 2010-2016
3.2.2 Revenue Forecast for Overall Drug Delivery Market, 2017-2025
3.3 Breakdown of the Global Drug Delivery Technology Market
3.3.1 Revenue Forecast for Oral Drug Delivery Technology, 2010-2016
3.3.2 Revenue Forecast for Oral Drug Delivery Technology, 2017-2025
3.3.3 Revenue Forecast for Inhalation Drug Delivery Technology, 2010-2016
3.3.4 Revenue Forecast for Inhalation Drug Delivery Technology, 2017-2025
3.3.5 Revenue Forecast for Transdermal Drug Delivery Technology, 2010-2016
3.3.6 Revenue Forecast for Transdermal Drug Delivery Technology, 2017-2025
3.3.7 Revenue Forecast for Injectable/Implant Drug Delivery Technology, 2010-2016
3.3.8 Revenue Forecast for Injectable/Implant Drug Delivery Technology, 2017-2025
3.3.9 Revenue Forecast for Ocular Drug Delivery Technology, 2010-2016
3.3.10 Revenue Forecast for Ocular Drug Delivery Technology, 2017-2025
3.3.11 Revenue Forecast for Nasal Drug Delivery Technology, 2010-2016
3.3.12 Revenue Forecast for Nasal Drug Delivery Technology, 2017-2025
3.4 National Markets for Drug Delivery Technology
3.4.1 Leading National Markets for Drug Delivery Technology, 2010-2025
3.4.2 The Japanese Drug Delivery Technology Market, 2010-2025
3.4.3 The Leading European Drug Delivery Technology Markets, 2010-2025
3.4.4 Emerging-Economy Drug Delivery Technology Markets
3.4.5 The Chinese Drug Delivery Technology Market, 2010-2025
3.4.6 The Indian Drug Delivery Technology Market, 2010-2025
4. Drug Classes that Can Benefit from Advances in Drug Delivery
4.1 Therapeutic Areas Offering Growth Opportunities
4.1.1 The Leading Biotech Therapy Classes, 2010-2025
4.1.2 The Top 10 Biotech Therapy Classes in 2009
4.1.3 The Oncology Class Currently Leads the Biotech Market
4.1.3.1 Long-Term Prospects in Oncology and Implications for the Drug Delivery Technology Market
4.1.4 The Human Insulins Class will Exhibit Strong Growth
4.1.5 Immunosuppressive Agents, 2010-2025
4.1.6 Autoimmune Agents Show Promising Growth - Will it Last?
4.1.7 Erythropoietin Products - How Will Reported Safety Affect Sales?
4.1.7.1 Erythropoietin Products Forecast, 2010-2025
4.1.8 Immunostimulating Agents - Sales Prospects
4.1.9 The Interferons Class Will Show an Increase in Revenues from 2010-2015
4.1.9.1 Long-Term Forecast for the Interferons Class
4.1.10 Vaccine Sales
4.1.10.1 Will Pure Vaccine Sales Decline from 2015?
4.1.11 Blood Coagulation Factors Will Show Steady Growth
4.1.12 Growth Hormones Forecast, 2010-2025
4.2 Summary of World Market Forecasts
4.2.1 Top 10 Biotech Therapy Classes, 2010-2025
4.2.2 Drug Delivery Technology Market: a Rapidly-Expanding Segment of the Global Pharma Sector
5. Some Prominent Companies in the Drug Delivery Technology Market
5.1 Introduction
5.2 Leading Oral Drug Delivery Companies
5.2.1 Applied Pharma Research (APR)
5.2.1.1 Overview
5.2.1.2 Therapeutic Areas and Technology
5.2.1.3 MonoSol Rx Announces FDA Approval of Zuplenz: An Oral Soluble Film for Treatment of Nausea and Vomiting
5.2.2 Catalent Pharma Solutions
5.2.2.1 Overview
5.2.2.2 Catalent's Oral Drug Delivery Technology
5.2.2.3 Catalent's Customer Base
5.2.2.4 Manufacturing Capabilities
5.2.2.5 Revenues
5.2.3 Emisphere Technologies
5.2.3.1 Overview
5.2.3.2 Emisphere's Eligen Technology
5.2.3.3 Emisphere's Pipeline Products
5.2.3.4 Emisphere's Partnered Programmes
5.2.3.5 Revenues
5.2.3.6 Future Outlook
5.2.4 Ethypharm
5.2.4.1 Overview
5.2.4.2 Ethypharm's Proprietary Technologies
5.2.4.3 Products on the Market
5.2.5 Eurand
5.2.5.1 Overview
5.2.5.2 Eurand's Drug Delivery Platforms
5.2.5.3 Pipeline Products/Indication
5.2.5.4 Revenue
5.2.5.5 Future Outlook
5.2.6 Glycologic Limited
5.2.6.1 Overview
5.2.6.2 Glycologic Technology Platform
5.2.6.3 Pipeline Products
5.2.6.4 Future Outlook
5.2.7 Penwest Pharmaceuticals
5.2.7.1 Overview
5.2.7.2 Penwest's Technology Platforms
5.2.7.3 Pipeline Products
5.2.7.4 Penwest's IP and Patents
5.2.7.5 Revenues
5.3 Inhaled Drug Delivery
5.3.1 3M Drug Delivery Systems
5.3.1.1 Overview
5.3.1.2 Protein and Peptide Delivery
5.3.1.3 Excipient Technology for CFC-Free Inhalers
5.3.1.4 Actuator Technology for MDIs
5.3.1.5 Particle Engineering Technology
5.3.1.6 Revenues
5.3.2 Aradigm Corp.
5.3.2.1 Overview
5.3.2.2 AERx Drug Delivery System
5.3.2.3 Aradigm Collaborations
5.3.2.4 Pipeline Products
5.3.2.5 Revenues
5.3.3 Vectura Group
5.3.3.1 Overview
5.3.3.2 Proprietary Technologies
5.3.3.3 Pipeline Products
5.3.3.4 Revenues
5.4 Injectable Drug Delivery
5.4.1 Alkermes
5.4.1.1 Overview
5.4.1.2 Proprietary Technology Platforms
5.4.1.3 Product Pipeline
5.4.1.4 Revenues
5.4.2 Pacira Pharmaceuticals
5.4.2.1 Overview
5.4.2.2 Injectable Sustained-Release Technology
5.4.2.3 Products
5.4.2.4 Pipeline
5.4.2.5 Revenues
5.4.2.6 Future Outlook
5.5 Transdermal Drug Delivery
5.5.1 3M
5.5.1.1 Overview
5.5.1.2 Transdermal Systems
5.5.2 Altea Therapeutics
5.5.2.1 Overview
5.5.2.2 Altea's PassPort Technology Platform
5.5.2.3 Therapeutic Focus
5.5.3 Intercell
5.5.3.1 Overview
5.5.3.2 Vaccine Patch Technology Platform
5.5.3.3 Intercell's Strategic Alliances
5.5.3.4 Revenues
5.5.4 NanoPass Technologies
5.5.4.1 Overview
5.5.4.2 Technology Platform
5.5.4.3 The MicronJet Needle
5.5.5 Noven Pharmaceuticals
5.5.5.1 Overview
5.5.5.2 Key Products
5.5.5.3 Transdermal Pipeline Products
5.5.5.4 Revenues
5.6 Transmucosal Drug Delivery
5.6.1 Overview
5.6.2 Cima Labs (Cephalon)
5.6.2.1 Overview
5.6.2.2 Cima's Transmucosal Drug Delivery Technologies
5.6.2.3 Products
5.6.3 Columbia Laboratories
5.6.3.1 Overview
5.6.3.2 Bioadhesive Delivery Technology
5.6.3.3 Products
5.6.3.4 Revenue
5.6.4 Generex Biotechnology Corporation
5.6.4.1 Overview
5.6.4.2 Products
5.6.4.3 Pipeline Products
5.6.4.4 Revenue
5.7 Implant Technology
5.7.1 Overview
5.7.2 pSivida Corp.
5.7.2.1 Overview
5.7.2.2 Technologies and Products
5.7.2.2.1 Durasert Technology System
5.7.2.2.2 BioSilicon Technology System
5.7.2.2.3 CODRUG Technology System
5.7.2.3 Products
5.7.2.4 Revenues
6. Drivers, Restraints and Trends in Drug Delivery
6.1 Analysis of Strengths, Weaknesses, Opportunities and Threats (SWOT), 2010-2025
6.2 Patent Expiry Will Drive Biological Drug Delivery
6.2.1 Biosimilars Legislation Encourages Innovation
6.2.2 As Patents Expire, Competition Will Increase
6.3 Competitive and Lucrative Monoclonal Antibody Market Will Drive Sales
6.4 Biological Drug Delivery Technology is Already Established
6.4.1 Controlled-Release Technologies
6.4.2 Exubera, Afrezza and Oral-lyn Show the Way for Innovative Technologies
6.4.3 The Emerging Nanotech Industry is Good News for Biological Drug Delivery
6.5 Will Regulatory Authorities Hold Back the Market?
6.5.1 Risk-Conscious FDA and EMA Will Make Approval Difficult?
6.5.2 Choice Between New Technology or a New Drug? Is a Rethink Required?
6.6 New Delivery Methods for Biologicals Must be Cost-Effective and Appropriate
6.7 Injection is Still the Main Form of Delivery
6.8 Next-Generation Drugs May Limit Drug-Delivery Revenues
6.8.1 Lifecycle Management via Protein Engineering Blurs Drug Delivery Lines
6.8.2 New Chemical Entities Could Restrict Biotech Growth
6.9 The Biological Drug Delivery Market Offers Great Potential, But Care is Required
7. Expert Views from the Sector
7.1 Expert Interview 1: Professor Sven Frokjaer, Dean, Faculty of Pharmaceutical Sciences, University of Copenhagen, Denmark
7.1.1 Current Market Value for Drug Delivery Systems
7.1.2 Key Benefits for Patients
7.1.3 On Emerging Technologies
7.1.4 On Nanotechnology
7.1.5 On Different Systems
7.1.6 Main Challenges Facing the Sector
7.1.7 On Nanoparticle Systems and Drug Delivery
7.1.8 Systems on the Market
7.1.9 Diseases of Interest
7.1.10 Therapeutic Areas Offering Opportunities
7.2 Expert Interview 2: Dr Bill Lambert, PhD, Senior Vice President, Pharmaceutical Development, Pacira Pharmaceuticals, San Diego, CA, USA
7.2.1 On Pacira and Drug Delivery Technology
7.2.2 Liposomal Drug Delivery
7.2.3 Applications of DepoFoam Technology
7.2.4 On Pacira's Products
7.2.5 Pipeline DDT Platforms
7.2.6 On the Market for Drug Delivery Technology
7.2.7 Therapeutic Areas Offering Market Opportunities
7.2.8 Challenges Facing the Drug Delivery Industry
7.2.9 Comparing DepoFoam with Other Controlled-Release Systems
7.2.10 Mode of Delivery
7.2.11 Insulin and Liposomal Drug Delivery
7.2.12 R&D and Technologies Likely to be on the Market in Future
8. Conclusions
8.1 The Market Shows Great Potential
8.2 Commercial Drivers for Drug Delivery Technology
8.3 Prominent Companies in the Market
8.4 Future Outlook and Concluding Remarks
List of Tables
Table 2.1 Top 10 Biotech Products on the Market, 2009
Table 2.2 Top 10 Biotech Companies, Revenues, 2008 and 2009
Table 2.3 Amino Acid Changes for Human Insulin Analogues
Table 3.1 Drug Delivery Technology Market: World Revenues, 2009-2016
Table 3.2 Drug Delivery Technology Market: World Revenues, 2017-2025
Table 3.3 Oral Drug Delivery Technology Market: World Revenues, 2009-2016
Table 3.4 Oral Drug Delivery Technology Market: World Revenues, 2017-2025
Table 3.5 Inhalation Drug Delivery Technology Market: World Revenues, 2009-2016
Table 3.6 Inhalation Drug Delivery Technology Market: World Revenues, 2017-2025
Table 3.7 Transdermal DDT Market: World Revenues, 2009-2016
Table 3.8 Transdermal DDT Market: World Revenues, 2017-2025
Table 3.9 Injectable/Implants DDT Market: World Revenues, 2009-2016
Table 3.10 Injectable/Implants DDT Market: World Revenues, 2017-2025
Table 3.11 Ocular Drug Delivery Technology Market: World Revenues, 2009-2016
Table 3.12 Ocular Drug Delivery Technology Market: World Revenues, 2017-2025
Table 3.13 Nasal Drug Delivery Technology Market: World Revenues, 2009-2016
Table 3.14 Nasal Drug Delivery Technology Market: World Revenues, 2017-2025
Table 3.15 Drug Delivery Technology Market: World Revenues, 2009-2016
Table 3.16 Drug Delivery Technology Market: World Revenues, 2017-2025
Table 3.17 Leading Drug Delivery Technology National Markets: Revenues, 2009-2015, 2020 & 2025
Table 4.1 The Top 10 Biotech Therapy Classes, 2009
Table 4.2 Oncology Class: World Sales, 2009-2016
Table 4.3 Oncology Class: World Sales, 2017-2025
Table 4.4 Human Insulins Class: World Sales, 2009-2016
Table 4.5 Human Insulins Class: World Sales, 2017-2025
Table 4.6 Immunosuppressive Agents Class: World Sales, 2009-2016
Table 4.7 Immunosuppressive Agents Class: World Sales, 2017-2025
Table 4.8 Autoimmune Agents Class: World Sales, 2009-2016
Table 4.9 Autoimmune Agents Class: World Sales, 2017-2025
Table 4.10 Erythropoietin Products Class: World Sales, 2009-2016
Table 4.11 Erythropoietin Products Class: World Sales, 2017-2025
Table 4.12 Immunostimulating Agents Class: World Sales, 2009-2016
Table 4.13 Immunostimulating Agents Class: World Sales, 2017-2025
Table 4.14 Interferons Class: World Sales, 2009-2016
Table 4.15 Interferons Class: World Sales, 2017-2025
Table 4.16 Pure Vaccines Class: World Sales, 2009-2016
Table 4.17 Pure Vaccines Class: World Sales, 2017-2025
Table 4.18 Blood Coagulation Factors Class: World Sales, 2009-2016
Table 4.19 Blood Coagulation Factors Class: World Sales, 2017-2025
Table 4.20 Growth Hormones Class: World Sales, 2009-2016
Table 4.21 Growth Hormones Class: World Sales, 2017-2025
Table 4.22 Leading Biotech Therapy Classes: World Sales, 2009-2016
Table 4.23 Leading Biotech Therapy Classes: World Sales, 2017-2025
Table 5.1 Approved Drugs Using Penwest's TIMERx Technology, 2010
Table 5.2 Penwest's Product Pipeline, 2010
Table 5.3 Alkermes' Product Pipeline, 2010
Table 5.4 Noven's Marketed Transdermal Products, 2010
Table 6.1 SWOT Analysis for the Drug Delivery Sector, 2010
Table 6.2 Some Leading Drugs Losing Patent Protection, 2010-2012
Table 6.3 Monoclonal Antibody Therapeutics Approved by US FDA, 1986-2003
Table 6.4 Monoclonal Antibody Therapeutics Approved by US FDA, 2003-2010
Table 6.5 Leading Biologic Drug Types, 2009
Table 8.1 Drug Delivery Technology Market: World Revenues, 2009, 2010, 2012, 2015, 2018, 2020 & 2025
List of Figures
Figure 3.1 Drug Delivery Technology Market: World Revenues, 2009-2016
Figure 3.2 Drug Delivery Technology Market: World Revenues, 2017-2025
Figure 3.3 Oral Drug Delivery Technology Market: World Revenues, 2009-2016
Figure 3.4 Oral Drug Delivery Technology Market: World Revenues, 2017-2025
Figure 3.5 Inhalation DDT Market: World Revenues, 2009-2016
Figure 3.6 Inhalation DDT Market: World Revenues, 2017-2025
Figure 3.7 Transdermal DDT Market: World Revenues, 2009-2016
Figure 3.8 Transdermal DDT Market: World Revenues, 2017-2025
Figure 3.9 Injectable/Implants DDT Market: World Revenues, 2009-2016
Figure 3.10 Injectable/Implants DDT Market: World Revenues, 2017-2025
Figure 3.11 Ocular Drug Delivery Technology Market: World Revenues, 2009-2016
Figure 3.12 Ocular Drug Delivery Technology Market: World Revenues, 2017-2025
Figure 3.13 Nasal Drug Delivery Technology Market: World Revenues, 2009-2016
Figure 3.14 Nasal Drug Delivery Technology Market: World Revenues, 2017-2025
Figure 3.15 Drug Delivery Technology Market: World Revenues, 2009-2025
Figure 3.16 US DDT Market: Revenues, 2009-2025
Figure 3.17 Other Leading DDT National Markets: Revenues, 2009-2025
Figure 3.18 DDT Revenue Shares for Leading National Markets, 2010
Figure 3.19 DDT Revenue Shares for Leading National Markets, 2015
Figure 3.20 DDT Revenue Shares for Leading National Markets, 2020
Figure 3.21 DDT Revenue Shares for Leading National Markets, 2025
Figure 4.1 Oncology Class: World Sales, 2009-2025
Figure 4.2 Human Insulins Class: World Sales, 2009-2025
Figure 4.3 Immunosuppressive Agents Class: World Sales, 2009-2025
Figure 4.4 Autoimmune Agents Class: World Sales, 2009-2025
Figure 4.5 Erythropoietin Products Class: World Sales, 2009-2025
Figure 4.6 Immunostimulating Agents Class: World Sales, 2009-2025
Figure 4.7 Interferons Class: World Sales, 2009-2025
Figure 4.8 Pure Vaccines Class: World Sales, 2009-2025
Figure 4.9 Blood Coagulation Factors Class: World Sales, 2009-2025
Figure 4.10 Growth Hormones Class: World Sales, 2009-2025
Figure 4.11 Leading Biotech Therapy Classes: World Sales, 2009-2025
Figure 4.12 Top Ten Therapy Classes: World Sales, 2009, 2015 & 2025
Figure 6.1 Different Approaches to Biological Drug Delivery
Figure 8.1 Drug Delivery Technology Market: World Revenue Forecasts by Category, 2009, 2010, 2012, 2015, 2018, 2020 & 2025
Figure 8.2 Drug Delivery Technology Market: Overall World Revenue Forecast, 2009, 2010, 2012, 2015, 2018, 2020 & 2025
Figure 8.3 Drug Delivery Technology Market: World Revenue Shares by Category, 2010
Companies Listed
3M Drug Delivery Systems
Abbott Laboratories
Actelion Pharmaceuticals
Alexion Pharmaceuticals
Alimera Sciences
Alkermes
Alpha M.O.S.
Altea Therapeutics
Alvogen
Amgen
Amylin Pharmaceuticals
Apotex Corp
Applied Pharma Research (APR)
Aradigm Corp
AstraZeneca
Bausch & Lomb
Baxter International
Bayer
Biocon
Biogen Idec
Biotech Pharmaceuticals
Boehringer Ingelheim
Bristol-Myers Squibb
Cardinal Health
Catalent Pharma Solutions
Celgene Corporation
Cell Therapeutics
Cephalon
Chiron Corporation
Cima Labs (Cephalon)
Columbia Laboratories
CSL Limited
Dr. Reddy's Laboratories
E. Merck KG
EKR Therapeutics
Elan Pharmaceuticals
Eli Lilly and Company
Elite Pharmaceuticals
Emisphere Technologies
Endo Pharmaceuticals
Ethypharm
Eurand Pharmaceuticals
Eurofarma
European Medicines Agency (EMA)
Flynn Pharma
Food and Drug Administration (US FDA)
Fresenius Group
Genentech (now part of Hoffmann-La Roche)
Generex Biotechnology Corporation
geneRx+
Genmab
Genta
Genzyme Corporation
Gilead Sciences
GlaxoSmithKline (GSK)
Glycologic Limited
Hisamitsu Pharmaceutical Co.
Hoffmann-La Roche
Intercell
Johnson & Johnson Services (J&J)
Labtec
Leiras OY (Nycomed)
MannKind Corporation
MonoSol Rx
MundiPharma
Mylan
NanoPass Technologies
National Institute for Health and Clinical Excellence (NICE, UK)
Nektar Therapeutics
Novartis Pharma
Noven Pharmaceuticals
Novo Nordisk
Novogyne Pharmaceuticals
Otsuka Pharmaceuticals Co
Pacira Pharmaceuticals
Par Pharmaceutical Companies
Penwest Pharmaceuticals
Pfizer
Pre-clinical Partnerships
pSivida Corp.
Ranbaxy Laboratories
Roche Biomedical Laboratories
Sanofi-Aventis
Sanofi-Synthelabo (now Sanofi-Aventis)
Schering-Plough Corporation (now part of Merck & Co.)
Shire
Sigma-Tau Pharmaceuticals
SkyePharma
Spectrum Pharmaceuticals
Strativa Pharmaceuticals
The Blackstone Group
TRION Pharma
UCB
Vectura Group
Whitehall Laboratories
Wyeth (now a part of Pfizer)
Zhejiang CONBA Pharmaceutical Co.
To order this report:
Drug Delivery Technology Industry: Drug Delivery Technologies: Commercial Prospects 2010-2025
Drug Delivery Technology Business News
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article